TNFRSF17 and Miyoshi myopathy: For the first time, clinical efficacy was confirmed in the OriCAR-017 (phase 1, POLARIS) and CARTITUDE-2 trials, where the patients with relapsing or refractory MM, who had earlier received BCMA-targeted therapy, reached an overall response rate (ORR) of 70–90% [120,121].